The present invention provides an effective combination method of a compound and microtubule agonist which have excellent selective inhibition of Aurora A and can be administered orally. The treatment method of the present invention is characterized in that it utilizes 1- (2,3-dichlorobenzyl) -4- [5-fluoro-6- (5-methyl-1H-pyrazol-3-yl Amino) pyridin-2-yl] methyl-4-piperidinecarboxylic acid (Compound I) or its salts and microtubule agonists are targeted at malignant tumors, and the schedule of administration is: The microtubule agonist was administered once within 7 days of the cycle, and the above Compound I or its salt was administered for 3 consecutive days, and the drug was discontinued for the remaining 4 days.本發明提供一種具有優異之Aurora A選擇性抑制作用且能夠經口投予之化合物與微管促效劑之有效之併用方法。本發明之治療方法之特徵在於：其係利用1-(2,3-二氯苯甲醯基)-4-[5-氟-6-(5-甲基-1H-吡唑-3-基胺基)吡啶-2-基]甲基-4-哌啶羧酸(化合物I)或其鹽與微管促效劑之組合進行之針對惡性腫瘤者，且其投予排程為：於1週期7天內投予1次微管促效劑，連續3天投予上述化合物I或其鹽，剩餘之4天停藥。
